John Gordan, MD, PhD

Assoc Professor In Residence
Medicine
+1 415 353-9888
Research Description: 

I am a physician scientist focused on the treatment and study of primary liver cancers. I attend in the Gastrointestinal Oncology Group and run a research group in the Quantitive Biosciences Institute. My laboratory applies proteomic methods to identify novel targets and improve the application of existing therapeutics for liver cancers including hepatocellular carcinoma, cholangiocarcinoma and fibrolamellar liver cancer. We have three major areas of investigation:
1. Mapping oncogenic kinase signaling and its response to targeted therapeutics to define biomarkers and combination treatments for clinically relevant agents
2. Characterizing the impact of hepatitis viruses on liver cancer and its response to treatment
3. Developing small molecule strategies to target Hippo pathway dysregulation

Primary Thematic Area: 
Cancer Biology & Cell Signaling
Secondary Thematic Area: 
None
Research Summary: 
The Gordan lab combines chemical biology with cancer systems biology strategies to identify new therapeutic targets and drug combinations for GI cancers.

Websites

Featured Publications: 

Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Gordan JD, Kennedy EB, Abou-Alfa GK, Beg MS, Brower ST, Gade TP, Goff L, Gupta S, Guy J, Harris WP, Iyer R, Jaiyesimi I, Jhawer M, Karippot A, Kaseb AO, Kelley RK, Knox JJ, Kortmansky J, Leaf A, Remak WM, Shroff RT, Sohal DPS, Taddei TH, Venepalli NK, Wilson A, Zhu AX, Rose MG

Unbiased Proteomic Profiling Uncovers a Targetable GNAS/PKA/PP2A Axis in Small Cell Lung Cancer Stem Cells.

Cancer cell

Coles GL, Cristea S, Webber JT, Levin RS, Moss SM, He A, Sangodkar J, Hwang YC, Arand J, Drainas AP, Mooney NA, Demeter J, Spradlin JN, Mauch B, Le V, Shue YT, Ko JH, Lee MC, Kong C, Nomura DK, Ohlmeyer M, Swaney DL, Krogan NJ, Jackson PK, Narla G, Gordan JD, Shokat KM, Sage J

KRASG12C inhibition produces a driver-limited state revealing collateral dependencies.

Science signaling

Lou K, Steri V, Ge AY, Hwang YC, Yogodzinski CH, Shkedi AR, Choi ALM, Mitchell DC, Swaney DL, Hann B, Gordan JD, Shokat KM, Gilbert LA

Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer.

Nature chemical biology

Donnella HJ, Webber JT, Levin RS, Camarda R, Momcilovic O, Bayani N, Shah KN, Korkola JE, Shokat KM, Goga A, Gordan JD, Bandyopadhyay S